Drug Database · Clinicians

Meclizine

Also known as: meclozine (international nonproprietary name and British name)

Brands (15) Bonamine, Eramel, Meclitab…Show all

US brand (reference label): Meclizine Hydrochloride; not a Philippine-registered brand.

Anti-emetic/ anti-vertigo; Anti-emetic/ antivertigo; and others PH FDA category

Rx · Prescription drugOTC · Over-the-counter26 PH products
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID c9ddc39c-bc6b-42f1-8c5f-5aff2d79c4bd, version date June 2, 2025 (Meclizine Hydrochloride · Rising Pharma Holdings, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.

Contraindications

4 CONTRAINDICATIONS Meclizine hydrochloride is contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see Adverse Reactions (6) and Description (11)]. Meclizine hydrochloride is contraindicated in patients with hypersensitivity to meclizine or any of the inactive ingredients.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

Recommended dosage: 25 mg to 100 mg daily, in divided doses (2.1). Tablets: Swallow whole (2.2). Chewable Tablets: Must be chewed or crushed before swallowing; do not swallow whole (2.2).

2.1 Recommended Dosage

2.1 Recommended Dosage The recommended dosage is 25 mg to 100 mg daily administered orally, in divided doses, depending upon clinical response.

2.2 Administration Instructions Tablets

2.2 Administration Instructions Tablets Meclizine hydrochloride tablets must be swallowed whole. Chewable Tablets Meclizine hydrochloride chewable tablets must be chewed or crushed completely before swallowing. Do not swallow chewable tablets whole.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations)

8.7 Renal Impairment The effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. Because of a potential for drug/metabolite accumulation, meclizine hydrochloride should be administered with caution in patients with renal impairment and in the elderly, as renal function generally declines with age.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. As meclizine hydrochloride undergoes metabolism, hepatic impairment may result in increased systemic exposure of meclizine. Treatment with meclizine hydrochloride should be administered with caution in patients with hepatic impairment.

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Administration

2.2 Administration Instructions Tablets Meclizine hydrochloride tablets must be swallowed whole. Chewable Tablets Meclizine hydrochloride chewable tablets must be chewed or crushed completely before swallowing. Do not swallow chewable tablets whole.

US FDA label

Dosage forms

Philippines

  • Chewable tablet: 12.5 mg, 25 mg
  • Tablet: 25 mg

Registered products in the Philippines

26 products registered with the Food and Drug Administration (FDA) Philippines list Meclizine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products26
Philippine FDA-registered products for Meclizine
Package insert
BonamineMeclizine Hydrochloride
12.5 mg Chewable TabletAlu/PVC Blister Pack x 10's and 30's (Box of 120's)
OTC
Interphil Laboratories, Inc.Philippines
Trader: Taisho Pharmaceuticals (Philippines), Inc.
DR-XY19867
Oct 21, 2029
BonamineMeclizine Hydrochloride
25 mg Chewable TabletAlu/PVC Blister pack x 10's (Box of 240's)
OTC
Interphil Laboratories, Inc.Philippines
Trader: Taisho Pharmaceuticals Philippines Inc.
DR-XY22028
May 22, 2029
BonazinMeclizine Hydrochloride
12.5 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-13361
Feb 6, 2028
Bonazin ForteMeclizine Hydrochloride
25 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.,Philippines
—
DRP-11990
Jun 6, 2027
EramelMeclizine Hydrochloride
12.5 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Errapel Pharmed Corp.
DRP-13361-01
Feb 6, 2028
EramelMeclizine Hydrochloride
25 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Errapel Pharmed Corp.
DRP-11990-01
Jun 6, 2027
MecligenMeclizine Hydrochloride
12.5 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Trader: EBA Generisch Trading Inc.
DRP-13191
Dec 22, 2027
Mecligen ForteMeclizine Hydrochloride
25 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-13360
Feb 6, 2028
MeclineMeclizine Hydrochloride
12.5 mg Chewable TabletClear PVC Blister Pack x 10's (Box of 100's)
OTC
Drugmaker’s Laboratories Inc.Laguna
—
DR-XY46823
Feb 4, 2032
MeclitabMeclizine Hydrochloride
12.5 mg Chewable TabletClear PVDC Blister Pack x 10's (Box of 100's)
OTC
Lloyd Laboratories, Inc.Philippines
TGP Pharma, Inc.Trader: D.B. Manix International, Inc.
DRP-10048
May 25, 2030
MeclitabMeclizine Hydrochloride
25 mg Chewable TabletClear PVDC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
TGP Pharma, Inc.Trader: D.B. Manix International, Inc.
DR-XY37989
May 25, 2030
MeclizanMeclizine Hydrochloride
25mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Triple 888 Medical And Pharma Inc.
DRP-11990-03
Jun 6, 2027
MeclizsaphMeclizine Hydrochloride
25 mg Chewable TabletAlu-clear/PVC Blister Pack x 10's (Box of 100's)
OTC
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-10228
Aug 13, 2031
MelzinMeclizine Hydrochloride
25mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Amiel Trading Inc.
DRP-11990-02
Jun 6, 2027
NoneMeclizine
25 mg Chewable TabletAlu-Clear PVC Blister Pack x 20's (Box of 100's)
Rx
Vonwelt, Inc.Philippines
—
DR-XY42804
Oct 11, 2030
NoneMeclizine
25 mg Chewable TabletAlu-Clear PVC Blister Pack x 20's (Box of 100's)
Rx
Vonwelt IncPhilippines
—
DRP-13537
Oct 11, 2030
NoneMeclizine Hydrochloride
25 mg Chewable TabletBlister Strip x 10s Box of 100's
OTC
Am-Europharma CorporationPhilippines
Trader: RITEMED PHILS., INC.
DRP-8269
Sep 19, 2029
NoneMeclizine Hydrochloride
25 mg Chewable TabletBlister Strip x 10's (Box of 100's)
Rx
Am-Europharma CorporationPhilippines
Trader: Ritemed Phils., Inc.
DRP-8638
Jan 21, 2030
NovomitMeclizine Hydrochloride
12.5 mg Chewable tabletAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Saga Lifesciences LimitedIndia
Hexagon Pharmaceuticals
DR-XY47358
Aug 16, 2036
NovomitMeclizine Hydrochloride
25 mg Chewable TabletAlu/PVC Blister Pack x 10's (Box of 100's)
OTC
Saga Lifesciences LimitedIndia
Hexagon Pharmaceuticals
DR-XY46605
Jun 4, 2029
RamecMeclizine Hydrochloride
12.5 mg Chewable TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.,Philippines
Trader: St. Raphael Archạngel Pharmaceutical Product Distribution
DRP-11989
May 26, 2027
Ramec ForteMeclizine Hydrochloride
25 mg Chewable Tablet (Orange Flavor)Alu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.,Philippines
Trader: St. Raphael Archangel Pharmaceutical Product Distribution
DRP-11955
Jun 6, 2027
UnbrandedMeclizine Hydrochloride
25 mg TabletAlu/PCDC/PVC Clear Blister pack x 10's (Box of 100's)
OTC
AM-EUROPHARMA CORPORATIONPhilippines
AM-EUROPHARMA CORPORATION
DRP-8280
Oct 22, 2029
United Home DizitabMeclizine Hydrochloride
25 mg Chewable TabletBlister Strip x 10's (Box of 100's)
OTC
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY32470
Oct 5, 2027
(no brand name)Meclizine hydrochloride
12.5 mg Chewable TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc,Philippines
—
DRP-14659
Nov 17, 2028
(no brand name)Meclizine hydrochloride
12.5 mg Chewable TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's)
OTC
Azarias Pharmaceutical Laboratories Inc.Philippines
Trader: Daily Grace Unlimited, Inc.
DRP-14824
Jan 17, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Tablets 12.5 mg: oval-shaped, biconvex, two-layered tablet, one blue to pale blue layer debossed with “34” and one white to off white layer debossed with “L”. 25 mg: oval-shaped, biconvex, two-layered tablet, one yellow to pale yellow layer debossed with “49” and one white to off white layer debossed with “L”. 50 mg: oval-shaped, biconvex, two-layered tablet, one blue to pale blue layer debossed with “50” and one yellow to pale yellow layer and debossed with “L”. Chewable Tablets 25 mg: pink colored round tablets debossed with “M 25” on one side and break line on other side.

Tablets: 12.5 mg, 25 mg, and 50 mg (3). Chewable Tablets: 25 mg (3).

Warnings/Precautions

Warnings and precautions (US label) US FDA label

May cause drowsiness: Use caution when driving a car or operating dangerous machinery (5.1). Potential anticholinergic action: this drug should be prescribed with care to patients with a history of asthma, glaucoma, or enlargement of the prostate gland (5.2).

5.1 Drowsiness

5.1 Drowsiness Since drowsiness may occur with use of meclizine hydrochloride, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery. Patients should avoid alcoholic beverages while taking meclizine hydrochloride [see Drug Interactions (7.1)].

5.2 Concurrent Medical Conditions

5.2 Concurrent Medical Conditions Because of its potential anticholinergic action, meclizine hydrochloride should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

Drug interactions

Drug interactions (US label) US FDA label

Coadministration of meclizine hydrochloride with other CNS depressants, including alcohol, may result in increased CNS depression (7.1). CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride and CYP2D6 inhibitors (7.2).

7.1 CNS Depressants

7.1 CNS Depressants There may be increased CNS depression when meclizine hydrochloride is administered concurrently with other CNS depressants, including alcohol [see Warnings and Precautions (5.1)].

7.2 CYP2D6 Inhibitors Based

7.2 CYP2D6 Inhibitors Based on in-vitro evaluation, meclizine is metabolized by CYP2D6. Therefore, there is a possibility for a drug interaction between meclizine hydrochloride and CYP2D6 inhibitors. Therefore, monitor for adverse reactions and clinical effect accordingly.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Metabolism In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine.

CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride and CYP2D6 inhibitors ( 7.2 ). 7.1 CNS Depressants There may be increased CNS depression when meclizine hydrochloride is administered concurrently with other CNS depressants, including alcohol [see Warnings and Precautions (5.1) ] . 7.2 CYP2D6 Inhibitors Based on in-vitro evaluation, meclizine is metabolized by CYP2D6.

Therefore, there is a possibility for a drug interaction between meclizine hydrochloride and CYP2D6 inhibitors.

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS The following adverse reactions associated with the use of meclizine hydrochloride were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported. Common adverse reactions are anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported (6). To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. However, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Human Data Epidemiological studies reporting on pregnancies exposed to meclizine have not identified an association between the use of meclizine during pregnancy and an increased risk of major birth defects.

Animal Data In a published study, oral administration of meclizine (25-250 mg/kg) to pregnant rats during the period of organogenesis resulted in a high incidence of fetal malformations. These effects occurred at doses as low as 25 mg/kg, which is approximately 2 times the maximum recommended human dose (100 mg) on a body surface area (mg/m2) basis.

Mechanism of action

12.1 Mechanism of Action The precise mechanism by which meclizine exerts its therapeutic effect is unknown but is presumed to involve antagonism of the histamine H1 receptor.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics There are no relevant pharmacodynamic data regarding meclizine.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination Meclizine has a plasma elimination half-life of about 5-6 hours in humans.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The available pharmacokinetic information for meclizine following oral administration has been summarized from published literature. Absorption Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median T max value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form.

Distribution Drug distribution characteristics for meclizine in humans are unknown. Elimination Meclizine has a plasma elimination half-life of about 5-6 hours in humans. Metabolism In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Meclizine Hydrochloride · Rising Pharma Holdings, Inc. [US FDA-approved label, version 3, June 2, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9ddc39c-bc6b-42f1-8c5f-5aff2d79c4bd
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .